Published : 13 Aug 2020
We have a new client, new assignment. A Texas based Pharma has appointed Aagami for divesting 2 oncology assets.
The client, after acquiring a novel oncology platform, is seeking divestiture opportunities for its complex generic Doxorubicin (asset1). Client has completed a substantial amount of nonclinical and clinical development, including a bioequivalence clinical study of the Doxorubicin asset versus the originator. Much of the data generated can be used to support regulatory filings and approvals in the United States, Europe, China, and other countries/regions.
Asset number 2, is a patented Docetaxel (Albumin-Stabilized PEGylated Liposomal Docetaxel) for Relapsed Small Cell Lung Cancer. Client has an open FDA-approved IND for patented Docetaxel. Client has completed and published results from a 29 patient U.S. Phase 1 clinical trial in solid tumors. Client is preparing to initiate a Phase 2 clinical trial with patented Docetaxel as a second-line therapy for relapsed small cell lung cancer.
Aagami team are excited to get the divestment done, soon. If you have an interest, please send an email to godwyn@aagami.com or call on +1-630-364-1837. We can send you a non-confidential deck for review.